Captrust Financial Advisors Has $317,000 Position in Henry Schein, Inc. (NASDAQ:HSIC)

Captrust Financial Advisors reduced its position in Henry Schein, Inc. (NASDAQ:HSIC) by 36.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,347 shares of the company’s stock after selling 2,490 shares during the quarter. Captrust Financial Advisors’ holdings in Henry Schein were worth $317,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in HSIC. ING Groep NV bought a new position in Henry Schein in the 3rd quarter valued at $63,226,000. Thompson Siegel & Walmsley LLC purchased a new position in Henry Schein in the 2nd quarter worth $46,683,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Henry Schein in the 3rd quarter valued at about $43,740,000. Bank of Montreal Can increased its stake in shares of Henry Schein by 365.6% in the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after buying an additional 558,689 shares during the period. Finally, SG Americas Securities LLC raised its position in Henry Schein by 1,622.3% during the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after purchasing an additional 432,187 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Down 0.6 %

Shares of NASDAQ:HSIC opened at $76.60 on Friday. The firm has a fifty day moving average price of $72.25 and a 200 day moving average price of $70.06. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The stock has a market cap of $9.55 billion, a P/E ratio of 31.52, a P/E/G ratio of 2.31 and a beta of 0.87. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. During the same period last year, the company posted $1.32 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year. Sell-side analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current year.

Insiders Place Their Bets

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. The trade was a 12.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Mizuho began coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price objective on the stock. Barrington Research reiterated an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research note on Wednesday, November 6th. Finally, Evercore ISI lifted their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.